Mirum Pharmaceuticals, Inc. (MIRM) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Mirum Pharmaceuticals is a biopharmaceutical company focused on rare diseases affecting children and adults. The company commercializes three approved medicines: LIVMARLI (maralixibat) for Alagille syndrome and PFIC, and the Bile Acid Medicines (Cholbam and Chenodal) acquired from Travere Therapeutics in August 2023. The company operates as a single segment and is currently in a growth phase, investing heavily in commercialization and clinical development.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $90,377 | $47,725 | $237,474 | $116,820 |
| Net Loss | $(14,235) | $(23,588) | $(64,152) | $(127,756) |
| Operating Loss | $(12,684) | $(25,148) | $(63,384) | $(76,569) |
| Cash & Equivalents | $222,969 | $303,059 | $222,969 | $303,059 |
| Total Investments | $70,797 | $0 | $70,797 | $0 |
| Convertible Notes (Principal) | $316,250 | $316,250 | $316,250 | $316,250 |
| Accumulated Deficit | $(620,391) | $(520,580) | $(620,391) | $(520,580) |
Liquidity: As of September 30, 2024, the company held unrestricted cash, cash equivalents, and investments of $293.8 million. Management believes this is sufficient to fund operations for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 91% year-over-year for Q3 2024 ($90.4M vs. $47.7M). This was driven by the full quarter impact of the Bile Acid Medicines (Cholbam and Chenodal) and continued growth in Livmarli sales.
- Product Mix: Livmarli sales were $59.1M in Q3 2024 (up 53% YoY). Bile Acid Medicines sales were $31.2M in Q3 2024 (up 246% YoY, as the prior year included only partial month sales post-acquisition).
- Expense Increases: Operating expenses rose to $103.1M in Q3 2024 from $72.9M in Q3 2023.
- Cost of Sales: Increased to $20.8M due to higher royalties, amortization of intangibles from the Travere acquisition, and product costs.
- R&D: Increased to $31.7M, primarily due to expanded clinical trials for volixibat (PSC and PBC studies).
- SG&A: Increased to $50.5M, driven by personnel growth to support commercialization and increased marketing spend.
- Net Loss Improvement: Net loss narrowed to $14.2M in Q3 2024 from $23.6M in Q3 2023, reflecting revenue growth outpacing expense increases.
Guidance, Outlook, and Risks
- Clinical Pipeline:
- Volixibat: Received FDA Breakthrough Therapy Designation for cholestatic pruritus in PBC. Phase 2b trials in PSC and PBC are ongoing.
- Chenodal: NDA for CTX submitted in June 2024 with a PDUFA date of December 28, 2024.
- Livmarli: Phase 3 EXPAND study expected to initiate in H2 2024.
- Recent Acquisition: In October 2024, the company acquired worldwide rights to MRM-3379 (formerly ENT-3379) for Fragile X Syndrome for an upfront payment of $7.5M and potential milestones up to $217.5M.
- Internal Controls: The company disclosed material weaknesses in internal control over financial reporting related to inventory valuation and fair value assessments. These weaknesses were present as of September 30, 2024, and management concluded disclosure controls were not effective, though financial statements are considered fairly presented.
- Competition: Chenodal and Cholbam face immediate competition from compounded and generic entrants as they lack patent protection. Livmarli faces competition from Ipsen's odevixibat (Bylvay/Kayfanda).
Investor Verification Checklist
- Inventory Valuation: Verify the remediation plan for material weaknesses regarding inventory existence and net realizable value, given the reliance on third-party manufacturers.
- Chenodal CTX Approval: Monitor the FDA decision on the Chenodal NDA for CTX (PDUFA: Dec 28, 2024), which is critical for revenue growth in this indication.
- Volixibat Trial Data: Review upcoming data readouts from the VISTAS (PSC) and VANTAGE (PBC) Phase 2b trials to assess commercial potential.
- Convertible Notes: Assess the impact of the $316.3M convertible notes (due 2029) on future dilution and cash flow obligations.
- Generic Competition: Evaluate the market share erosion risks for Chenodal and Cholbam due to the lack of patent exclusivity.